Is there an increased risk of cancer?
Two factors must be known before that question can be answered. First, information on exposures (or doses) to individual members of the population under consideration must be calculated. Second, health problems that the population experienced after the exposure must be identified. From this information, a risk estimate can be made. Risk estimates are based on statistical calculations. For mathematical reasons, risk estimates are more supportable if there has been a large number of people exposed and their range of doses is large. We still lack sufficient information to assess the risk to people exposed to the Hanford radiation releases because there is no comprehensive information on the health of those exposed. Additionally, dose estimates for specific individuals are not yet available. Regarding the list of radioactive materials for which doses are being calculated, I am limiting my comments to the radioactive elements with which I have some experience: plutonium-239 and iodine-131.
No increased risk of developing cancer of the breast, ovaries, uterus, cervix, or liver is associated with use of the shot. In fact, the shot may even decrease the risk of uterine cancer. Getting the shot The injection is given into a large muscle in either the arm or the buttock. Most women say the shot is not painful, but the injection site can remain sore for about a day. A newer version of the shot is injected under the skin on the abdomen or front of the thigh. Timeline The first injection is given only during the first five days of a normal menstrual period or within five days after childbirth. Given this way, the shot is effective immediately. Subsequent injections must be given within 11 to 13 weeks of the pervious shot. To be sure not to miss follow-up injections, try the following: • Make the next appointment before leaving the clinic after getting a shot. • Mark the date on a calendar. • Visit www.depo-provera.com to sign up for a confidential email reminder program. If 13 w
Depo Provera health risks include breast cancer and osteoporosis. Depo Provera Contraceptive Injective (CI) was developed in the 1960s and had been approved for birth control in many other countries except the United States. The Upjohn Company (now Pfizer) first submitted it for approval in the United States in the in the 1970s. At that time animal studies raised questions about its potential to cause breast cancer. It wasnt until 1992 that the FDA approved DEPO PROVERA for U.S. use. According to the FDA memo, it said that worldwide studies have since found the overall risk of cancer, including breast cancer in humans, to be minimal, if any. DEPO PROVERA and cancer Womens health groups in other countries have also highlighted previously identified risks to womens health such as an increased risk of breast, uterine, and cervical cancers. Though previously mentioned and a concern, they are now just being addressed. Please take the time to answer the questionnaire if you have or had osteo
